Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.60 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.51 |
| ▸ | SELE | P16581 | 2/20 | 0.51 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102501 | 0.89 | RXFP1 (0.76) | PRNPTSHRMAPK1PPARGHTT | |
| Ammonia Solution, Strong SCHEMBL28931345 | 0.88 | RXFP1 (0.74) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL5212677 | 0.87 | RXFP1 (0.60) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL3050845 | 0.86 | HTT (0.46) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL9433072 | 0.86 | PRNP (0.81) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL6656891 | 0.86 | MAPK1 (0.58) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL9375035 | 0.84 | MCL1 (0.48) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL8877598 | 0.81 | MCL1 (0.56) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL5034019 | 0.81 | ICAM1 (0.55) | PRNPTSHRMAPK1PPARGHTT | |
| SCHEMBL6196210 | 0.81 | RXFP1 (0.53) | PRNPTSHRMAPK1PPARGHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0731800-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO [b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1996-09-18 | — | — | EP | claimed |
| US-5426191-A | Treating substituted cinnamic acids with 4-N,N*-disubstituted aminopyridines, then with thionyl chloride | WARNER-LAMBERT COMPANY (US) | 1995-06-20 | — | — | US | claimed |
| WO-1995015323-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO[b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1995-06-08 | — | — | WO | claimed |
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2011-06-16 | — | — | US | disclosed |
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2011-06-16 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| EP-1585745-A4 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | TRILLIUM THERAPEUTICS INC (CA) | 2008-07-09 | — | — | EP | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-5489586-A | BENZOTHIOPHEN, BENZOFURAN AND INDOLE-THIAZEPINONES, OXAZEPINONES AND DIAZEPINONES | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| WO-1995024408-A1 | BENZOTHIOPHENE, BENZOFURAN AND INDOLETHIAZEPINONES, OXAZEPINONES AND DIAZEPINONES AS INHIBITORS OF CELL ADHESION AND AS INHIBITORS OF HIV | WARNER-LAMBERT COMPANY (US) | 1995-09-14 | — | — | WO | disclosed |
| US-5426191-A | Treating substituted cinnamic acids with 4-N,N*-disubstituted aminopyridines, then with thionyl chloride | WARNER-LAMBERT COMPANY (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1995015323-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLOROBENZO[b]THIOPHENE-2-CARBONYL CHLORIDES | WARNER-LAMBERT COMPANY (US) | 1995-06-08 | — | — | WO | disclosed |
| US-5350748-A | 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion | WARNER-LAMBERT COMPANY (US) | 1994-09-27 | — | — | US | disclosed |
| EP-0299457-B1 | Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome | WARNER LAMBERT CO (US) | 1994-09-21 | — | — | EP | disclosed |
| US-4931459-A | ADMINISTERING SUBSTITUTED BENZOTHIOPHENES OR BENZOFURANS | WARNER-LAMBERT COMPANY (US) | 1990-06-05 | — | — | US | disclosed |
| US-4910317-A | Containing a 5-amidetetrazole substitution in position 2 | WARNER-LAMBERT COMPANY (US) | 1990-03-20 | — | — | US | disclosed |
| EP-0299457-A2 | Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome | WARNER-LAMBERT COMPANY (US) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | FCGR1A, FCGR2A, FCGR3B | PRNP 2326/4885TSHR 116/4885MAPK1 3146/4885 |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | FCGR1A, FCGR2A, FCGR3B | PRNP 2326/4885TSHR 116/4885MAPK1 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.